Stock comparison
Side-by-side financials for AUTL and MRNA. Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Market cap data is available for the leading company in this comparison.
Market value leader
MRNA
Latest market capitalization comparison.
Revenue leader
MRNA
AUTL: $75.39M vs MRNA: $1.94B.
Profit leader
AUTL
AUTL: -$287.53M vs MRNA: -$2.82B.
Margin leader
MRNA
AUTL: -381.4% vs MRNA: -145.2% net margin.
| Metric | AUTL | MRNA |
|---|---|---|
| Market cap | - | $30.38 B |
| US-listed rank | - | #461 |
| Revenue (latest FY) | $75.39M | $1.94B |
| Net income (latest FY) | -$287.53M | -$2.82B |
| Net margin | -381.4% | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 305 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
In their latest fiscal years, Autolus Therapeutics plc reported $75.39M in revenue while Moderna, Inc. reported $1.94B.
Full pages: Autolus Therapeutics plc and Moderna, Inc., or browse the full rankings.